The safety profile and efficacy of MSCs are well-established based on the results from a number of completed clinical studies investigating the therapeutic potential of these therapies in lung diseases such as ARDS (Matthay et al., 2019; Chen J. et al., 2020) and bronchopulmonary dysplasia (Namba, 2019), cardiovascular diseases (Kim et al., 2015; Suvakov et al., 2020), diabetes (Thakkar et al., 2015; Cho et al., 2018), and spinal cord injury (Xu and Yang, 2019).